S Siesling1, W J Louwman2, A Kwast3, C van den Hurk4, M O'Callaghan5, S Rosso6, R Zanetti7, H Storm8, H Comber9, E Steliarova-Foucher10, J W Coebergh11. 1. Department of Registration and Research, Comprehensive Cancer Centre the Netherlands, Utrecht, The Netherlands; Department of Health Technology and Services Research, MIRA Institute for Technical Medicine and Biomedical Technology, University of Twente, Enschede, The Netherlands. Electronic address: s.siesling@iknl.nl. 2. Research Department, Comprehensive Cancer Centre the Netherlands, location Eindhoven (formerly IKZ), The Netherlands. Electronic address: m.louwman@iknl.nl. 3. Department of Registration and Research, Comprehensive Cancer Centre the Netherlands, Utrecht, The Netherlands. Electronic address: a.kwast@iknl.nl. 4. Research Department, Comprehensive Cancer Centre the Netherlands, location Eindhoven (formerly IKZ), The Netherlands. Electronic address: c.vandenhurk@iknl.nl. 5. National Cancer Registry of Ireland, Cork, Ireland. Electronic address: m.ocallaghan@ncri.ie. 6. Piedmont Cancer Registry, CPO, Turin, Italy. Electronic address: stefano.rosso@cpo.it. 7. Piedmont Cancer Registry, CPO, Turin, Italy. Electronic address: roberto.zanetti@cpo.it. 8. Danish Cancer Society, Copenhagen, Denmark. Electronic address: hans@cancer.dk. 9. National Cancer Registry of Ireland, Cork, Ireland. Electronic address: h.comber@ncri.ie. 10. International Agency for Research on Cancer, Lyon, France. Electronic address: SteliarovaE@iarc.fr. 11. Research Department, Comprehensive Cancer Centre the Netherlands, location Eindhoven (formerly IKZ), The Netherlands; Department of Public Health, Erasmus MC Rotterdam, The Netherlands. Electronic address: coebergh@planet.nl.
Abstract
AIM: To provide insight into cancer registration coverage, data access and use in Europe. This contributes to data and infrastructure harmonisation and will foster a more prominent role of cancer registries (CRs) within public health, clinical policy and cancer research, whether within or outside the European Research Area. METHODS: During 2010-12 an extensive survey of cancer registration practices and data use was conducted among 161 population-based CRs across Europe. Responding registries (66%) operated in 33 countries, including 23 with national coverage. RESULTS: Population-based oncological surveillance started during the 1940-50s in the northwest of Europe and from the 1970s to 1990s in other regions. The European Union (EU) protection regulations affected data access, especially in Germany and France, but less in the Netherlands or Belgium. Regular reports were produced by CRs on incidence rates (95%), survival (60%) and stage for selected tumours (80%). Evaluation of cancer control and quality of care remained modest except in a few dedicated CRs. Variables evaluated were support of clinical audits, monitoring adherence to clinical guidelines, improvement of cancer care and evaluation of mass cancer screening. Evaluation of diagnostic imaging tools was only occasional. CONCLUSION: Most population-based CRs are well equipped for strengthening cancer surveillance across Europe. Data quality and intensity of use depend on the role the cancer registry plays in the politico, oncomedical and public health setting within the country. Standard registration methodology could therefore not be translated to equivalent advances in cancer prevention and mass screening, quality of care, translational research of prognosis and survivorship across Europe. Further European collaboration remains essential to ensure access to data and comparability of the results.
AIM: To provide insight into cancer registration coverage, data access and use in Europe. This contributes to data and infrastructure harmonisation and will foster a more prominent role of cancer registries (CRs) within public health, clinical policy and cancer research, whether within or outside the European Research Area. METHODS: During 2010-12 an extensive survey of cancer registration practices and data use was conducted among 161 population-based CRs across Europe. Responding registries (66%) operated in 33 countries, including 23 with national coverage. RESULTS: Population-based oncological surveillance started during the 1940-50s in the northwest of Europe and from the 1970s to 1990s in other regions. The European Union (EU) protection regulations affected data access, especially in Germany and France, but less in the Netherlands or Belgium. Regular reports were produced by CRs on incidence rates (95%), survival (60%) and stage for selected tumours (80%). Evaluation of cancer control and quality of care remained modest except in a few dedicated CRs. Variables evaluated were support of clinical audits, monitoring adherence to clinical guidelines, improvement of cancer care and evaluation of mass cancer screening. Evaluation of diagnostic imaging tools was only occasional. CONCLUSION: Most population-based CRs are well equipped for strengthening cancer surveillance across Europe. Data quality and intensity of use depend on the role the cancer registry plays in the politico, oncomedical and public health setting within the country. Standard registration methodology could therefore not be translated to equivalent advances in cancer prevention and mass screening, quality of care, translational research of prognosis and survivorship across Europe. Further European collaboration remains essential to ensure access to data and comparability of the results.
Authors: Wilfred Ngwa; Beatrice W Addai; Isaac Adewole; Victoria Ainsworth; James Alaro; Olusegun I Alatise; Zipporah Ali; Benjamin O Anderson; Rose Anorlu; Stephen Avery; Prebo Barango; Noella Bih; Christopher M Booth; Otis W Brawley; Jean-Marie Dangou; Lynette Denny; Jennifer Dent; Shekinah N C Elmore; Ahmed Elzawawy; Diane Gashumba; Jennifer Geel; Katy Graef; Sumit Gupta; Serigne-Magueye Gueye; Nazik Hammad; Laila Hessissen; Andre M Ilbawi; Joyce Kambugu; Zisis Kozlakidis; Simon Manga; Lize Maree; Sulma I Mohammed; Susan Msadabwe; Miriam Mutebi; Annet Nakaganda; Ntokozo Ndlovu; Kingsley Ndoh; Jerry Ndumbalo; Mamsau Ngoma; Twalib Ngoma; Christian Ntizimira; Timothy R Rebbeck; Lorna Renner; Anya Romanoff; Fidel Rubagumya; Shahin Sayed; Shivani Sud; Hannah Simonds; Richard Sullivan; William Swanson; Verna Vanderpuye; Boateng Wiafe; David Kerr Journal: Lancet Oncol Date: 2022-05-09 Impact factor: 54.433
Authors: Wojciech Krajewski; Katarzyna Kościelska-Kasprzak; Joanna Rymaszewska; Romuald Zdrojowy Journal: Qual Life Res Date: 2017-01-03 Impact factor: 4.147
Authors: Miguel Angel Luque-Fernandez; Aurélien Belot; Linda Valeri; Giovanni Cerulli; Camille Maringe; Bernard Rachet Journal: Am J Epidemiol Date: 2018-04-01 Impact factor: 4.897
Authors: Laura Biganzoli; Fatima Cardoso; Marc Beishon; David Cameron; Luigi Cataliotti; Charlotte E Coles; Roberto C Delgado Bolton; Maria Die Trill; Sema Erdem; Maria Fjell; Romain Geiss; Mathijs Goossens; Christiane Kuhl; Lorenza Marotti; Peter Naredi; Simon Oberst; Jean Palussière; Antonio Ponti; Marco Rosselli Del Turco; Isabel T Rubio; Anna Sapino; Elzbieta Senkus-Konefka; Marko Skelin; Berta Sousa; Tiina Saarto; Alberto Costa; Philip Poortmans Journal: Breast Date: 2020-02-26 Impact factor: 4.380